By focusing on areas such as cardiovascular health and weight management, new therapies can provide comprehensive solutions that improve patient outcomes and quality of life
As the regulatory landscape surrounding GLP-1 medications continues to evolve, healthcare providers, patients, and compounding pharmacies must navigate a complex intersection of medical need, legal boundaries, and public health priorities
Whilst transdermal patch formulations represent an area of ongoing pharmaceutical research, no GLP-1 patches are currently licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) or approved by the National Institute for Health and Care Excellence (NICE) for use in the United Kingdom
The benefit of improved therapeutic effect with higher doses should be weighed against the possibility of a greater incidence of adverse reactions
Intake of catechin increases glucose uptake in rat skeletal muscle, possibly via GLUT4 translocation [41,42]